The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-13
SponsorUniversity of Colorado, Denver

About this trial

This study is designed to research the natural history of neurodevelopment, health and early hormonal function in infants with XXY/Klinefelter syndrome, XYY, XXX and other sex chromosome variations in an effort to identify early predictors of developmental and health outcomes. The Investigators will also evaluate different developmental screening tools in infants with sex chromosome variations so the investigators can develop recommendations for pediatrician caring for infants and young children with XXY/Klinefelter syndrome, XYY, XXX, and other sex chromosome variations.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Prenatal diagnosis of sex chromosome aneuploidy (by cfDNA, chorionic villi sampling, and/or amniocentesis)

Postnatal confirmatory karyotype of XXY, XYY, XXX, XXYY, XYYY, XXXY, XXXX, XXXXX, XXXXY, XXXYY, XXYYY, XYYYY (including any mosaicism with <80% 46,XX or 46,XY cell line)

English or Spanish speaking

Age 6 weeks to 12 months 30 days on enrollment

Disqualifiers

Previous diagnosis of a different genetic or metabolic disorder with neurodevelopmental or endocrine involvement

Prematurity less than 34 weeks gestational age

Complex congenital malformation not previously associated with sex chromosome aneuploidy

History of significant neonatal complications (ie intraventricular hemorrhage, meningitis, hypoxic-ischemic encephalopathy)

Trial population

Sex Chromosome Trisomies (SCT) including Klinefelter (XXY), Trisomy X (XXX), and XYY. Rare sex tetrasomy and pentasomy conditions are also eligible.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Assessments of Development and Growth

    Other intervention

    Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: SCT Conditions1 intervention

Trial outcomes

Primary outcomes

1

Longitudinal Descriptive Statistics of Cognitive Scores on the Bayley-III

Cognitive skills will be assessed using the standardized Bayley Scales of Infant Development--3rd Edition (Bayley-3)

Time frame
36 months
2

Longitudinal Descriptive Statistics of Motor Scores on the Bayley-III

Motor development will be assessed using the standardized Bayley Scales of Infant Development--3rd Edition (Bayley-3)

Time frame
36 months
3

Longitudinal Descriptive Statistics of Language Scores on Bayley-III

Language development will be assessed using the Bayley Scales of Infant Development--3rd Edition (Bayley-3)

Time frame
36 months

Secondary outcomes

1

Body Mass Index (BMI)

BMI will be determined through measurement of length and weight at the research visit.

Time frame
36 months
2

Z Score

The z score will be calculated for age group at the research visit.

Time frame
36 months
3

Body Composition (% body fat)

Body fat percentage will be measured using air Dual Energy X-Ray Absorptiometry (DEXA) at 3 year old visit.

Time frame
3 year old visit

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.